IN8bio, Inc. (INAB) shareholders
Close on Nov 17, 2026Market cap $8.08MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Bios Advisors Gp, LLC Joint filing with Bios Capital Management, LP (9.99%), Aaron G.L. Fletcher (9.99%) and 4 more | 9,120,073 | 9.90% | 13D (active) amendment | May 2, 2025 |
| Lytton-Kambara Foundation Joint filing with Lytton Laurence W (9.99%) | 1,056,513 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| Stonepine Capital, L.P. Joint filing with Stonepine Capital Management, LLC (9.90%), Stonepine GP, LLC (9.90%) and 1 more | 1,007,990 | 9.90% | 13G (passive) | Dec 19, 2025 |
| Lytton Laurence W Joint filing with Lytton-Kambara Foundation (9.99%) | 984,031 | 9.99% | 13G (passive) | Dec 22, 2025 |
| Alyeska Investment Group, L.P. Joint filing with Alyeska Fund GP, LLC (9.90%), Anand Parekh (9.90%) | 966,381 | 9.90% | 13G (passive) | Dec 31, 2025 |
| Franklin Advisers, Inc. Joint filing with Franklin Resources, Inc. (9.40%) | 914,531 | 9.40% | 13G (passive) | Dec 31, 2025 |
| 683 Capital Management, LLC Joint filing with 683 Capital Partners, LP (7.86%), Ari Zweiman (7.86%) | 770,445 | 7.86% | 13G (passive) | Dec 22, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of INAB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Alyeska Investment Group, L.P. | 944,319 | 9.58% | $1.33M | – | 0.00% |
| Franklin Resources Inc | 914,531 | 9.28% | $1.29M | – | 0.00% |
| 683 Capital Management, LLC | 724,637 | 7.35% | $1.02M | – | 0.05% |
| Stonepine Capital Management, LLC | 695,287 | 7.05% | $980.36K | +31,875 | 0.55% |
| Vanguard Capital Management LLC | 88,865 | 0.90% | $126.54K | – | 0.00% |
| BIOS Capital Management, LP | 80,957 | 0.82% | $114.15K | −86,848 | 0.27% |
| Geode Capital Management, LLC | 72,550 | 0.74% | $102.30K | −13,689 | 0.00% |
| Citadel Advisors LLC | 63,055 | 0.64% | $88.91K | New | 0.00% |
| Oppenheimer & Co Inc | 63,042 | 0.64% | $88.89K | +39,009 | 0.00% |
| Vanguard Fiduciary Trust Co | 43,570 | 0.44% | $62.04K | – | 0.00% |
| Captrust Financial Advisors | 33,295 | 0.34% | $46.95K | – | 0.00% |
| Texas Capital Bank Wealth Management Services Inc | 24,406 | 0.25% | $34.41K | +656 | 0.00% |
| Northern Trust Corp | 21,734 | 0.22% | $30.65K | +1,294 | 0.00% |
| Renaissance Technologies LLC | 12,100 | 0.12% | $17.06K | New | 0.00% |
| Tower Research Capital LLC (TRC) | 3,738 | 0.04% | $5.27K | +2,473 | 0.00% |
| Northwestern Mutual Wealth Management Co | 2,785 | 0.03% | $3.93K | – | 0.00% |
| Jones Financial Companies Lllp | 768 | 0.01% | $1.04K | – | 0.00% |
| BlackRock, Inc. | 84 | 0.00% | $118 | – | 0.00% |
| Rockefeller Capital Management L.P. | 83 | 0.00% | $117 | – | 0.00% |
| Barclays PLC | 28 | 0.00% | $39 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 21 | 4M | 38.4% | 3 / 5 | 3 / 1 | 0M | 0M |
| Q1 2026 | 19 | 4M | 38.1% | 3 / 4 | 6 / 5 | 1M | 0M |
| Q4 2025 | 22 | 3M | 32.7% | 7 / 7 | 6 / 4 | 2M | 0M |
| Q3 2025 | 19 | 1M | 9.9% | 8 / 4 | 3 / 1 | 0M | 0M |
| Q2 2025 | 12 | 1M | 8.9% | 1 / 7 | 4 / 17 | 0M | 0M |
| Q1 2025 | 28 | 1M | 7.3% | 6 / 6 | 7 / 4 | 0M | 0M |
| Q4 2024 | 26 | 1M | 10.2% | 5 / 10 | 6 / 5 | 1M | 0M |
| Q3 2024 | 26 | 0M | 2.6% | 6 / 6 | 6 / 5 | 0M | 0M |
| Q2 2024 | 26 | 0M | 2.6% | 3 / 9 | 5 / 9 | 0M | 0M |
| Q1 2024 | 32 | 0M | 2.9% | 6 / 8 | 7 / 4 | 0M | 0M |
| Q4 2023 | 30 | 0M | 2.9% | 9 / 7 | 6 / 0 | 0M | 0M |
| Q3 2023 | 21 | 0M | 0.8% | 3 / 8 | 3 / 4 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
8 funds held INAB in Q2 2026, 18% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of INAB | Value | % of fund | As of |
|---|---|---|---|---|---|
| Franklin Biotechnology Discovery Fund | 332,083 | 3.37% | $345.37K | 0.03% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 88,865 | 0.90% | $125.30K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 63,611 | 0.65% | $118.95K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 8,320 | 0.08% | $15.56K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 2,040 | 0.02% | $3.81K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 567 | 0.01% | $1.06K | 0.00% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 200 | 0.00% | $282 | 0.00% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 0 | 0.00% | $0 | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| William Tai-Wei Ho | CEO, Director | 124,817 | 1.27% | May 12, 2026 |
| Kate Rochlin | President and COO | 9,085 | 0.09% | May 12, 2026 |
| Patrick McCall | CHIEF FINANCIAL OFFICER | 9,482 | 0.10% | May 12, 2026 |
| Lawrence Lamb | EVP and CSO | 101,369 | 1.03% | May 12, 2026 |
| Emily Fairbairn | Director | 0 | – | May 29, 2026 |
| Luba Greenwood | Director | 7,826 | 0.08% | May 12, 2026 |
| Peter C. Brandt | Director | 98,690 | 1.00% | May 12, 2026 |
| Jeremy R. Graff | Director | 4,549 | 0.05% | May 12, 2026 |
| Corinne Epperly | Director | 81,967 | 0.83% | May 12, 2026 |
| Alan S. Roemer | Director | 49,514 | 0.50% | Dec 23, 2025 |
| Travis Whitfill | Director | – | – | Dec 23, 2024 |
| BIOS Advisors GP, LLC | 10% owner | 540,287 | 5.48% | May 7, 2025 |
| BIOS Fund II QP, LP | 10% owner | 8,600,001 | 87.24% | May 7, 2025 |
| BIOS Fund II NT, LP | 10% owner | 561,989 | 5.70% | May 7, 2025 |
| BP Directors, LP | 10% owner | 8,600,001 | 87.24% | May 7, 2025 |
| Cavu Advisors, LLC | 10% owner | 559,076 | 5.67% | May 7, 2025 |
| BIOS Incysus Co-Invest I, LP | 10% owner | – | – | May 7, 2025 |
| BIOS Equity Partners III, LP | 10% owner | – | – | May 7, 2025 |
| BIOS Fund III, LP | 10% owner | – | – | May 7, 2025 |
| BIOS Fund III QP, LP | 10% owner | 570,724 | 5.79% | May 7, 2025 |
| BIOS Fund III NT, LP | 10% owner | 8,600,001 | 87.24% | May 7, 2025 |
| Cavu Management, LP | 10% owner | 3,612,569 | 36.64% | May 7, 2025 |
| Leslie W. Kreis | 10% owner | 570,724 | 5.79% | May 7, 2025 |
| Aaron G.L. Fletcher | 10% owner | – | – | May 7, 2025 |
| Bios Equity COF, LP | 10% owner | – | – | May 7, 2025 |
| Bios Clinical Opportunity Fund, LP | 10% owner | – | – | May 7, 2025 |
| Bios Equity Partners II, LP | 10% owner | 8,600,001 | 87.24% | May 7, 2025 |
| BIOS Fund II, LP | 10% owner | 8,600,001 | 87.24% | May 7, 2025 |
| BIOS Capital Management, LP | 10% owner | 8,600,001 | 87.24% | May 7, 2025 |
| Bios Equity Partners, LP | 10% owner | – | – | May 7, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Emily Fairbairn Director | May 27, 2026 | Gift | −724,637 | – | – | 0 |
| Peter C. Brandt Director | Dec 22, 2025 | Award | +72,464 | $1.38 | $100.00K | 95,181 |
| Patrick McCall CHIEF FINANCIAL OFFICER | Dec 22, 2025 | Award | +7,247 | $1.38 | $10.00K | 9,482 |
| William Tai-Wei Ho PRESIDENT AND CEO, Director, 10% owner | Dec 22, 2025 | Award | +36,232 | $1.38 | $50.00K | 121,168 |
| Emily Fairbairn Director | Dec 22, 2025 | Award | +724,637 | $1.38 | $1,000.00K | 724,637 |
| Kate Rochlin Chief Operating Officer | Dec 22, 2025 | Award | +7,247 | $1.38 | $10.00K | 9,085 |
| Alan S. Roemer Director | Dec 22, 2025 | Award | +36,232 | $1.38 | $50.00K | 49,514 |
| Peter C. Brandt Director | Apr 30, 2025 | Option exercise | +81,967 | $0.18 | $14.75K | 681,538 |
| Peter C. Brandt Director | Apr 30, 2025 | Option exercise | +81,967 | $0.18 | $14.75K | 599,571 |
| Patrick McCall CHIEF FINANCIAL OFFICER | Apr 30, 2025 | Option exercise | +15,000 | $0.18 | $2.70K | 67,071 |
| Kate Rochlin Chief Operating Officer | Apr 30, 2025 | Option exercise | +12,295 | $0.18 | $2.21K | 55,169 |
| Alan S. Roemer Director | Apr 30, 2025 | Option exercise | +102,459 | $0.18 | $18.44K | 387,489 |
| Alan S. Roemer Director | Apr 30, 2025 | Option exercise | +11,000 | $0.18 | $1.98K | 398,489 |
| Patrick McCall CHIEF FINANCIAL OFFICER | Oct 4, 2024 | Award | +25,316 | – | – | 52,071 |
| Alan S. Roemer Director | Oct 4, 2024 | Award | +126,582 | – | – | 285,030 |
| Kate Rochlin Chief Operating Officer | Oct 4, 2024 | Award | +25,316 | – | – | 42,874 |
| Peter C. Brandt Director | Oct 4, 2024 | Award | +253,164 | – | – | 517,604 |
| William Tai-Wei Ho PRESIDENT AND CEO, Director, 10% owner | Oct 4, 2024 | Award | +126,582 | – | – | 2,548,094 |
| William Tai-Wei Ho President and CEO, Director, 10% owner | Dec 13, 2023 | Award | +81,967 | – | – | 2,421,512 |
| Lawrence Lamb EVP and CSO | Dec 13, 2023 | Award | +1,639 | – | – | 101,369 |
| Trishna Goswami Chief Medical Officer | Dec 13, 2023 | Award | +4,098 | – | – | 6,729 |
| Peter C. Brandt Director | Dec 13, 2023 | Award | +81,967 | – | – | 264,440 |
| Kate Rochlin Chief Operating Officer | Dec 13, 2023 | Award | +12,295 | – | – | 17,558 |
| Alan S. Roemer Director | Dec 13, 2023 | Award | +102,459 | – | – | 158,448 |
| Corinne Epperly Director | Dec 13, 2023 | Award | +81,967 | – | – | 81,967 |
| Jeremy R. Graff Director | Dec 13, 2023 | Award | +2,049 | – | – | 4,549 |
| Patrick McCall Chief Financial Officer | Dec 13, 2023 | Award | +20,492 | – | – | 26,755 |
| Jeremy R. Graff Director | Sep 13, 2023 | Buy | +2,500 | $0.95 | $2.38K | 2,500 |
| Patrick McCall Chief Financial Officer | Aug 25, 2023 | Buy | +1,000 | $1.03 | $1.03K | 6,263 |
| William Tai-Wei Ho President and CEO, Director, 10% owner | Aug 24, 2023 | Buy | +23,800 | $1.05 | $24.99K | 2,339,545 |
| Emily Fairbairn Director | Jul 28, 2023 | Other | −4,111,958 | – | – | 0 |
| Leslie W. Kreis Director, 10% owner | Dec 12, 2022 | Buy | +8,735 | $2.48 | $21.66K | 570,724 |
| Leslie W. Kreis Director, 10% owner | Dec 12, 2022 | Buy | +9,214 | $2.48 | $22.85K | 601,980 |
| Leslie W. Kreis Director, 10% owner | Dec 12, 2022 | Buy | +57,052 | $2.48 | $141.49K | 3,727,597 |
| BIOS Fund III QP, LP Director, 10% owner | Dec 12, 2022 | Buy | +8,735 | $2.48 | $21.66K | 570,724 |
| BIOS Fund III QP, LP Director, 10% owner | Dec 12, 2022 | Buy | +9,214 | $2.48 | $22.85K | 601,980 |
| BIOS Fund III QP, LP Director, 10% owner | Dec 12, 2022 | Buy | +57,052 | $2.48 | $141.49K | 3,727,597 |
| BIOS Fund II NT, LP Director, 10% owner | Sep 28, 2022 | Buy | +2,913 | $2.02 | $5.88K | 561,989 |
| BIOS Fund II NT, LP Director, 10% owner | Sep 28, 2022 | Buy | +19,017 | $2.02 | $38.41K | 3,670,545 |
| BIOS Fund II NT, LP Director, 10% owner | Sep 28, 2022 | Buy | +3,070 | $2.02 | $6.20K | 592,766 |
| Bios Equity Partners II, LP Director, 10% owner | Sep 28, 2022 | Buy | +2,913 | $2.02 | $5.88K | 561,989 |
| Bios Equity Partners II, LP Director, 10% owner | Sep 28, 2022 | Buy | +19,017 | $2.02 | $38.41K | 3,670,545 |
| Bios Equity Partners II, LP Director, 10% owner | Sep 28, 2022 | Buy | +3,070 | $2.02 | $6.20K | 592,766 |
| Cavu Advisors, LLC Director, 10% owner | Aug 29, 2022 | Buy | +4,660 | $2.02 | $9.41K | 559,076 |
| Cavu Advisors, LLC Director, 10% owner | Aug 29, 2022 | Buy | +4,912 | $2.02 | $9.92K | 589,696 |
| Cavu Advisors, LLC Director, 10% owner | Aug 29, 2022 | Buy | +30,428 | $2.02 | $61.46K | 3,651,528 |
| BIOS Fund II QP, LP Director, 10% owner | Aug 29, 2022 | Buy | +4,660 | $2.02 | $9.41K | 559,076 |
| BIOS Fund II QP, LP Director, 10% owner | Aug 29, 2022 | Buy | +4,912 | $2.02 | $9.92K | 589,696 |
| BIOS Fund II QP, LP Director, 10% owner | Aug 29, 2022 | Buy | +30,428 | $2.02 | $61.46K | 3,651,528 |
| Cavu Advisors, LLC Director, 10% owner | Aug 26, 2022 | Buy | +1,377 | $2.01 | $2.77K | 584,784 |
| Cavu Advisors, LLC Director, 10% owner | Aug 26, 2022 | Buy | +8,531 | $2.01 | $17.15K | 3,621,100 |
| Cavu Advisors, LLC Director, 10% owner | Aug 26, 2022 | Buy | +1,306 | $2.01 | $2.63K | 554,416 |
| BIOS Fund II QP, LP Director, 10% owner | Aug 26, 2022 | Buy | +1,377 | $2.01 | $2.77K | 584,784 |
| BIOS Fund II QP, LP Director, 10% owner | Aug 26, 2022 | Buy | +8,531 | $2.01 | $17.15K | 3,621,100 |
| BIOS Fund II QP, LP Director, 10% owner | Aug 26, 2022 | Buy | +1,306 | $2.01 | $2.63K | 554,416 |
| Cavu Management, LP Director, 10% owner | Aug 17, 2022 | Buy | +38,035 | $1.93 | $73.41K | 3,612,569 |
| Cavu Management, LP Director, 10% owner | Aug 17, 2022 | Buy | +5,823 | $1.93 | $11.24K | 553,110 |
| Cavu Management, LP Director, 10% owner | Aug 17, 2022 | Buy | +6,142 | $1.93 | $11.85K | 583,407 |
| BIOS Fund II NT, LP Director, 10% owner | Aug 17, 2022 | Buy | +5,823 | $1.93 | $11.24K | 553,110 |
| BIOS Fund II NT, LP Director, 10% owner | Aug 17, 2022 | Buy | +38,035 | $1.93 | $73.41K | 3,612,569 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of IN8bio's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.
See a number that looks wrong?